PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD

References

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009 Nov 19;361(21):2066–2078.
   PubMed Web of Science ®Google Scholar
• de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13–27.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016 Jan 7;7:e135.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment (anti-TNF, vedolizumab and ustekinumab) in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2019 Nov 28:jjz195. DOI:10.1093/ecco-jcc/jjz195.
   Google Scholar
• Sabino J, Verstockt B, Vermeire S, et al. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol. 2019;12:1756284819853208.
   Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018 Dec 23;390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720–727.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Rosenstein AK, Mehandru S, et al. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol. 2018 Nov;11(6):1558–1570.
   PubMed Web of Science ®Google Scholar
• Ma C, Battat R, Dulai PS, et al. Innovations in oral therapies for inflammatory bowel disease. Drugs. 2019 Aug;79(12):1321–1335.
   PubMed Web of Science ®Google Scholar
• Rekic D, Reynolds KS, Zhao P, et al. Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access. J Pharm Sci. 2017 Sep;106(9):2214–2218.
   PubMed Web of Science ®Google Scholar
• Deng R, Jin F, Prabhu S, et al. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):141–160.
   PubMed Web of Science ®Google Scholar
• Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012 Apr;91(4):635–646.
   PubMed Web of Science ®Google Scholar
• Ferl GZ, Theil FP, Wong H. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications. Biopharm Drug Dispos. 2016 Mar;37(2):75–92.
   PubMed Web of Science ®Google Scholar
• Posner J, Barrington P, Brier T, et al. Monoclonal Antibodies: past, Present and Future. Handb Exp Pharmacol. 2019;260:81–141.
   PubMedGoogle Scholar
• Hemperly A, Sandborn WJ, Vande Casteele N. Clinical pharmacology in adult and pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2018 Nov 29;24(12):2527–2542.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008 Nov;84(5):548–558.
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):687–709.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006 Jan;11(1–2):81–88.
   PubMed Web of Science ®Google Scholar
• Perez-Jeldres T, Tyler CJ, Boyer JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front Pharmacol. 2019;10:212.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L. Filgotinib in Crohn’s disease: JAK is back. Gastroenterology. 2017 Aug;153(2):603–605.
   PubMedGoogle Scholar
• Mould DR. The pharmacokinetics of biologics: A primer. Dig Dis. 2015;33(Suppl 1):61–69.
   PubMed Web of Science ®Google Scholar
• Ganellin R, Jefferis R, Roberts S. Similarities and Differences in the discovery, development and use of biopharmaceuticals versus small molecule drugs. Introduction to biological and small molecule drug research and development: theory and case studies. 1st ed. Amsterdam, Netherlands: Elsevier; 2013. p. 161–203.
   Google Scholar
• Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003 Nov;3(11):900–911.
   PubMed Web of Science ®Google Scholar
• Varyani F, Argyriou K, Phillips F, et al. Profile of tofacitinib in the treatment of ulcerative colitis: an evidence-based review of recent data. Drug Des Devel Ther. 2019;13:4091–4105.
   PubMed Web of Science ®Google Scholar
• Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G155–G162.
   PubMed Web of Science ®Google Scholar
• Danese S, Argollo M, Le Berre C, et al. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019 Oct;68(10):1893–1899.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Sabino J. Efficacy of anti-JAK inhibitors in ulcerative colitis. J Crohns Colitis. 2019 Dec 27:jjz202. DOI:10.1093/ecco-jcc/jjz202.
   PubMedGoogle Scholar
• Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 Aug 3;377(5):496–497.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 May 4;376(18):1723–1736.
   PubMed Web of Science ®Google Scholar
• Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 June;66(6):1049–1059.
   PubMed Web of Science ®Google Scholar
• Lamba M, Wang R, Fletcher T, et al. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol. 2016 Nov;56(11):1362–1371.
   PubMed Web of Science ®Google Scholar
• Klamerus KJ, Alvey C, Li L, et al. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2. Clin Pharmacol Drug Dev. 2014 Nov;3(6):499–507.
   PubMed Web of Science ®Google Scholar
• Lawendy N, Lamba M, Chan G, et al. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor. Clin Pharmacol Drug Dev. 2014 Nov;3(6):421–427.
   PubMed Web of Science ®Google Scholar
• Krishnaswami S, Chow V, Boy M, et al. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J Clin Pharmacol. 2014 Jan;54(1):46–52.
   PubMed Web of Science ®Google Scholar
• EMA EMA. Xeljanz - summary of product characteristics. 2017 [updated 2020 Mar 3; cited 2020 Mar 14]. Available from: https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf
   Google Scholar
• Gupta P, Chow V, Wang R, et al. Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects. Clin Pharmacol Drug Dev. 2014 Jan;3(1):72–77.
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Kostine M, Poursac N. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2013 June;9(6):753–761.
   PubMed Web of Science ®Google Scholar
• Pfizer I XELJANZ/XELJANZ XR (Tofacitinib) Product Monograph -drug interactions. 2017 [updated Mar 2019; cited 2020 Mar 14]. Available from: https://www.pfizermedicalinformation.ca/en-ca/xeljanz/drug-interactions#
   Google Scholar
• Gupta P, Alvey C, Wang R, et al. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. Br J Clin Pharmacol. 2012 July;74(1):109–115.
   PubMed Web of Science ®Google Scholar
• Menon S, Riese R, Wang R, et al. Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. Clin Pharmacol Drug Dev. 2016 Sep;5(5):336–342.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Fiorino G, Furfaro F, et al. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018 July;27(7):595–599.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017 Jan 21;389(10066):266–275.
   PubMed Web of Science ®Google Scholar
• Galien R, Vayssière B, de Vos S, et al. Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy volunteers and rheumatoid arthritis patients (Abstract 478). 2013 ACR/ARHP annual meeting; San Diego (CA); 2013.
   Google Scholar
• Labetoulle R, Paul S, Roblin X. Filgotinib for the treatment of Crohn’s disease. Expert Opin Investig Drugs. 2018 Mar;27(3):295–300.
   PubMed Web of Science ®Google Scholar
• Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015 Aug;54(8):859–874.
   PubMed Web of Science ®Google Scholar
• Anderson K, Zheng H, Kotecha M, et al. The relative bioavailability and effects of food and acid-reducing agents on filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019 July;8(5):585–594.
   PubMed Web of Science ®Google Scholar
• Sharma S, Xin Y, Gao C, et al. Population pharmacokinetics and exposure‐response of filgotinib in patients with moderate to severe Crohn’s disease. (Poster M-54). American conference of pharmacometrics; Bellevue (WA); 2016.
   Google Scholar
• Namour F, Vayssière B, Galien R, et al. Filgotinib (GLPG0634), a selective JAK1 inhibitor, shows similar pharmacokinetics and pharmacodynamics profiles in Japanese and Caucasian healthy volunteers (Abstract 2763). 2015 ACR/ARHP Annual Meeting; San Francisco (CA); 2015.
   Google Scholar
• Namour F, Fagard L, Van der Aa A, et al. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol. 2018 Dec;84(12):2779–2789.
   PubMed Web of Science ®Google Scholar
• Anderson K, Zheng H, Medzihradsky O, et al. THU0117 PHARMACOKINETICS AND SHORT-TERM SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT. Ann Rheum Dis. 2019;78(Suppl 2):331.
   Google Scholar
• Namour F, Desrivot J, Van der Aa A, et al. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett. 2016;10(1):38–48.
   PubMedGoogle Scholar
• Begley R, Anderson K, Watkins TR, et al. Lack of drug-drug interaction between filgotinib, a JAK-1 selective inhibitor, and a representative hormonal contraceptive medication, levonorgestrel/ethinyl estradiol (Abstract 1459). 2017 ACR/ARHP Annual Meeting; San Diego (CA); 2017.
   Google Scholar
• Rogler G. JAK efficacy in Crohn’s disease. J Crohns Colitis. 2019;jjz186.doi:10.1093/ecco-jcc/jjz186 .
   Google Scholar
• Sandborn WJ, Feagan BG, Panes J, et al. 874h - safety and efficacy of ABT-494 (Upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with Crohn’s disease: results from celest. Gastroenterology. 2017 [cited 2017 Apr 1];152(5, Supplement 1):S1308–S1309.
   Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panés J, et al. Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to-severely active ulcerative colitis: data from the phase 2B study U-ACHIEVE. United European Gastroenterol J. 2018;6(8 Suppl):A1–A134.
   Google Scholar
• Mohamed MF, Jungerwirth S, Asatryan A, et al. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol. 2017 Oct;83(10):2242–2248.
   PubMed Web of Science ®Google Scholar
• Klunder B, Mittapalli RK, Mohamed MF, et al. Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045–1058.
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Camp HS, Jiang P, et al. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016 Dec;55(12):1547–1558.
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Zeng J, Marroum PJ, et al. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clin Pharmacol Drug Dev. 2019 Feb;8(2):208–216.
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Feng T, Enejosa JV, et al. Effects of upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome P450 probe substrates: a study with the modified cooperstown 5+1 cocktail. J Clin Pharmacol. 2020 Jan;60(1):86–95.
   PubMedGoogle Scholar
• Mohamed MF, Trueman S, Feng T, et al. Characterization of the effect of renal impairment on upadacitinib pharmacokinetics. J Clin Pharmacol. 2019 June;59(6):856–862.
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Trueman S, Feng T, et al. The JAK1 inhibitor upadacitinib has no effect on the pharmacokinetics of levonorgestrel and ethinylestradiol: a study in healthy female subjects. J Clin Pharmacol. 2019 Apr;59(4):510–516.
   PubMed Web of Science ®Google Scholar
• Perez-Jeldres T, Tyler CJ, Boyer JD, et al. Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on basic pathogenesis concepts. Inflamm Bowel Dis. 2019 Jan 10;25(2):270–282.
   PubMed Web of Science ®Google Scholar
• Biswas S, Bryant RV, Travis S. Interfering with leukocyte trafficking in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2019 Feb - Apr;38–39:101617.
   PubMed Web of Science ®Google Scholar
• Karuppuchamy T, Behrens EH, Gonzalez-Cabrera P, et al. Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol. 2017 Jan;10(1):162–171.
   PubMed Web of Science ®Google Scholar
• Parigi TL, Roda G, Argollo M, et al. Is there a role for therapeutic sphingolipids in inflammatory bowel disease? Expert Rev Gastroenterol Hepatol. 2020 Jan;14(1):47–54.
   PubMed Web of Science ®Google Scholar
• Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016 June;173(11):1778–1792.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Hartung JP, Peach RJ, et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J Clin Pharmacol. 2017 Aug;57(8):988–996.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016 May 5;374(18):1754–1762.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Danese S, et al. Endoscopic and clinical efficacy demonstrated with oral ozanimod in moderately to severely active Crohn’s disease: 669. Am J Gastroenterol. 2017;112:S371.
   Web of Science ®Google Scholar
• Feagan BG, D’Haens G, Usiskin K, et al. P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial. J Crohn’s Colitis. 2019;13(Supplement_1):S450–S450.
   Google Scholar
• Juif PE, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):879–895.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Hartung JP, Tompkins CA, et al. Effects of high- and low-fat meals on the pharmacokinetics of ozanimod, a novel sphingosine-1-phosphate receptor modulator. Clin Pharmacol Drug Dev. 2018 Aug;7(6):634–640.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Hartung JP, Olson AD, et al. Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT/QTc study. Clin Pharmacol Drug Dev. 2018 Mar;7(3):263–276.
   PubMed Web of Science ®Google Scholar
• Al-Shamma H, Lehmann-Bruinsma K, Carroll C, et al. The selective sphingosine 1-phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis. J Pharmacol Exp Ther. 2019 June;369(3):311–317.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020 Feb;158(3):550–561.
   PubMed Web of Science ®Google Scholar
• NHI NLoM. Etrasimod versus placebo as induction therapy in moderately to severely active ulcerative colitis (ELEVATE UC 12). NCT03996369. [cited 2020 Mar 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT03996369
   Google Scholar
• NHI NLoM. Etrasimod versus placebo for the treatment of moderately to severely active ulcerative colitis (ELEVATE UC 52). NCT03945188. [cited 2020 Mar 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT03945188
   Google Scholar
• NHI NLoM. An extension study for treatment of moderately to severely active ulcerative colitis (ELEVATE UC OLE). NCT03950232. [cited 2020 Mar 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT03950232
   Google Scholar
• Lee CA, Acevedo L, Oh DA, et al. P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects. J Crohn’s Colitis. 2020;14(Supplement_1):S368–S368.
   Google Scholar
• Oh DA, Lee CA, Tang Y, et al. Steady-state trough concentrations and their relationship to selected demographic and clinical response measures in etrasimod-treated patients with moderately-to-severely active ulcerative colitis. World congress of gastroenterology; Istanbul (Turkey); 2019.
   Google Scholar
• Schreiber S, Morgan M, Christopher R, et al. Etrasimod (APD334), a potent, selective, oral S1P receptor modulator with preclinical autoimmune disease-modifying activity exhibits favorable PK/PD properties in healthy volunteers. (P180). Advances in inflammatory bowel diseases annual meeting; Orlando (FL); 2016.
   Google Scholar
• Peyrin-Biroulet L, Morgan M, Christopher R, et al. P-179 Safety, pharmacokinetics and pharmacodynamics of etrasimod (APD334), an oral selective S1P receptor modulator, after dose-escalation, in healthy volunteers. Inflamm Bowel Dis. 2017;23(suppl_1):S60–S61.
   Google Scholar
• Peyrin-Biroulet L, Morgan M, Christopher R, et al. Safety, pharmacokinetics and pharmacodynamics of etrasimod (APD334), an oral selective S1P receptor modulator, after single dose-escalation, in healthy volunteers. 2017 [cited 2020 May 27]. Poster. Available from: http://www.arenapharm.com/wp-content/uploads/2016/12/407C1DC3.pdf
   Google Scholar
• Lee CA, Oh DA, Tang Y, et al. Mass Balance, metabolic disposition, and pharmacokinetics of [14 C] etrasimod following oral administration to healthy male volunteers. AAPS 2019 PHarmSCi 360; San Antonio (TX); 2019.
   Google Scholar
• Lee CA, Oh DA, Tang Y, et al. PII-111 - disposition of [14C]etrasimod following oral administration to healthy male volunteers and role of cyp2c in formation of oxidative metabolites. ASCPT 2020 annual meeting; Huston (TX); 2020.
   Google Scholar
• Sun J, Shen X, Dong J, et al. Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function. Int Immunopharmacol. 2015 Dec;29(2):423–432.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Colombel JF, et al. A phase II study of laquinimod in Crohn’s disease. Gut. 2015 Aug;64(8):1227–1235.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Rutgeerts P, et al. P386 pharmacokinetics of laquinimod in patients with active moderate to severe Crohn’s disease. J Crohn’s Colitis. 2014;8(Supplement_1):S226–S226.
   Google Scholar
• Thone J, Linker RA. Laquinimod in the treatment of multiple sclerosis: a review of the data so far. Drug Des Devel Ther. 2016;10:1111–1118.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Tumani H, Sehr T, et al. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. J Neuroinflammation. 2017 Aug 31;14(1):172.
   PubMedGoogle Scholar
• Fernandez O. Oral laquinimod treatment in multiple sclerosis. Neurologia. 2011 Mar;26(2):111–117.
   PubMed Web of Science ®Google Scholar
• Tuvesson H, Hallin I, Persson R, et al. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos. 2005 June;33(6):866–872.
   PubMed Web of Science ®Google Scholar
• Elgart A, Zur AA, Mimrod D, et al. The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women. Eur J Clin Pharmacol. 2019 Jan;75(1):41–49.
   PubMed Web of Science ®Google Scholar
• EMA EMA. Refusal of the marketing authorisation for Nerventra (Laquinimod). Outcome of re-examination 2014. [updated 2014 Sep 1; cited 2020 Mar 14]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/nerventra-epar-refusal-public-assessment-report_en.pdf
   Google Scholar